KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $517000.0.

  • CRISPR Therapeutics AG's Capital Expenditures rose 10354.33% to $517000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $914000.0, marking a year-over-year decrease of 5192.0%. This contributed to the annual value of $914000.0 for FY2025, which is 5192.0% down from last year.
  • As of Q4 2025, CRISPR Therapeutics AG's Capital Expenditures stood at $517000.0, which was up 10354.33% from $74000.0 recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Capital Expenditures ranged from a high of $37.0 million in Q3 2021 and a low of $74000.0 during Q3 2025
  • For the 5-year period, CRISPR Therapeutics AG's Capital Expenditures averaged around $6.6 million, with its median value being $2.6 million (2023).
  • Per our database at Business Quant, CRISPR Therapeutics AG's Capital Expenditures skyrocketed by 63858.53% in 2021 and then tumbled by 8966.01% in 2024.
  • Over the past 5 years, CRISPR Therapeutics AG's Capital Expenditures (Quarter) stood at $9.2 million in 2021, then crashed by 32.58% to $6.2 million in 2022, then crashed by 88.08% to $738000.0 in 2023, then crashed by 65.58% to $254000.0 in 2024, then surged by 103.54% to $517000.0 in 2025.
  • Its Capital Expenditures was $517000.0 in Q4 2025, compared to $74000.0 in Q3 2025 and $117000.0 in Q2 2025.